Tumor neoantigenicity metric improves prediction of response to immunotherapyFebruary 22, 2020ImmunotherapyLung CancerRenal Cell CarcinomaMelanoma
Banning indoor tanning devices could save lives and moneyFebruary 20, 2020MelanomaNonmelanoma Skin Cancer
Smartphone apps for suspicious skin lesions unreliableFebruary 11, 2020Nonmelanoma Skin CancerMelanoma
FDA: Cell phones still look safeFebruary 11, 2020Mixed TopicsCNS/Brain CancerBreast CancerLung CancerLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationGynecologic Cancer
Global project reveals cancer’s genomic playbookFebruary 5, 2020Mixed TopicsCNS/Brain CancerBreast CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersHead & Neck/Thyroid CancersGynecologic Cancer
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumorsJanuary 31, 2020Renal Cell CarcinomaImmuno-oncologyGenitourinary CancerMelanomaLung CancerGynecologic CancerHead & Neck/Thyroid Cancers
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortalityJanuary 16, 2020Lung CancerMelanomaGynecologic CancerPatient & Survivor Care
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitorsJanuary 11, 2020ImmunotherapyLung CancerMelanoma
Combo elicits lasting responses in metastatic melanomaNovember 25, 2019MelanomaImmunotherapyImmuno-oncology
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanomaNovember 12, 2019MelanomaImmunotherapyImmuno-oncology
